Skip to main content

Thalomid Side Effects

Generic name: thalidomide

Medically reviewed by Drugs.com. Last updated on May 27, 2024.

Note: This document provides detailed information about Thalomid Side Effects associated with thalidomide. Some dosage forms listed on this page may not apply specifically to the brand name Thalomid.

Applies to thalidomide: oral capsule.

Important warnings This medicine can cause some serious health issues

Oral route (capsule)

Thalidomide can cause severe birth defects or embryofetal death, even with 1 dose, if taken during pregnancy.

Thalidomide distribution is restricted through the THALOMID REMS(TM) program (formerly known as the S.T.E.P.S.® program).

The use of thalidomide in multiple myeloma patients results in an increased risk of VTE , such as DVT and pulmonary embolism.

Coadministration of dexamethasone increases this risk.

Monitor for thromboembolism and consider thromboprophylaxis for individualized cases.

Serious side effects of Thalomid

Along with its needed effects, thalidomide (the active ingredient contained in Thalomid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking thalidomide:

More common side effects

  • anxiety
  • black, tarry stools
  • chest pain
  • chills
  • confusion
  • cough
  • dizziness or lightheadedness
  • dry mouth
  • fainting
  • fast heartbeat
  • fever
  • irregular heartbeat
  • irritability
  • loss of taste
  • lower back or side pain
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle weakness
  • nervousness
  • numbness and tingling around the mouth, fingertips, or feet
  • pain in the chest, groin, or legs, especially the calves
  • pain, redness, or swelling in the arm or leg
  • painful or difficult urination
  • pale skin
  • peeling and loosening of the skin
  • restlessness
  • seizures
  • severe, sudden headache
  • skin rash
  • shakiness in the legs, arms, hands, or feet
  • slurred speech
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • stomach cramps
  • sudden, unexplained shortness of breath
  • sudden loss of coordination
  • sudden, severe weakness or numbness in the arm or leg
  • swollen glands
  • tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area
  • tingling, burning, numbness, or pain in the hands, arms, feet, or legs
  • trembling or shaking of hands or feet
  • trouble sleeping
  • troubled breathing
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vision changes

Rare side effects

  • blood in the urine
  • decreased urination

Incidence not known

  • bleeding gums
  • blistering of the skin
  • blood in the stools
  • difficulty with speaking
  • inability to move the arms, legs, or facial muscles
  • inability to speak
  • itching skin
  • muscle jerking of the arms and legs
  • pinpoint red spots on the skin
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • slow speech
  • sudden loss of consciousness

Other side effects of Thalomid

Some side effects of thalidomide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

  • constipation
  • dry skin
  • diarrhea
  • dizziness
  • drowsiness
  • loss of appetite
  • nausea
  • stomach pain
  • weight changes

Less common side effects

  • headache
  • increased appetite

For healthcare professionals

Applies to thalidomide: oral capsule.

General adverse events

In uncontrolled studies with HIV-seropositive patients, there were reports of adverse events (e.g., increased HIV viral load, decreased CD4 count, AIDS) that were not reported in other patient populations; consult the manufacturer product information.[Ref]

Metabolic

Other

Gastrointestinal

Nervous system

Hematologic

Respiratory

Musculoskeletal

Dermatologic

Psychiatric

Cardiovascular

Endocrine

Hepatic

Genitourinary

Ocular

Hypersensitivity

Immunologic

Oncologic

Renal

References

1. (2001) "Product Information. Thalomid (thalidomide)." Celgene Corporation

2. Duong DJ, Spigel GT, Moxley RT, Gaspari AA (1999) "American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus." Arch Dermatol, 135, p. 1079-87

3. Fox MR, Harris A (2001) "Intractable insomnia after cessation of treatment with thalidomide." Gastroenterology, 120, p. 1567-8

4. Atra E, Sato EI (1993) "Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide." Clin Exp Rheumatol, 11, p. 487-93

5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie (1999) "Antitumor activity of thalidomide in refractory multiple myeloma." N Engl J Med, 341, p. 1565-71

6. Peuckmann V, Fisch M, Bruera E (2000) "Potential novel uses of thalidomide - Focus on palliative care." Drugs, 60, p. 273-92

7. Aronson IK, Yu R, West DP, Van Den Brock H, Antel J (1984) "Thalidomide-induced peripheral neuropathy." Arch Dermatol, 120, p. 1466-70

8. Keesal N, Wasserman MJ, Bookman A, Lapp V, Weber DA, Keystone EC (1999) "Thalidomide in the treatment of refractory rheumatoid arthritis." J Rheumatol, 26, p. 2344-7

9. Vasiliauskas EA, Kam LY, AbreuMartin MT, Hassard PV, Papadakis KA, Yang HY, Zeldis JB, Targan SR (1999) "An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease." Gastroenterology, 117, p. 1278-87

10. Sohlbach K, Heinze S, Shiratori K, Sure U, Pagenstecher A, Neubauer A (2006) "Encephalopathy in a patient after long-term treatment with thalidomide." J Clin Oncol, 24, p. 4942-4

11. Duyvendak M, Naunton M, Kingma BJ, Brouwers JR (2005) "Thalidomide-associated thrombocytopenia." Ann Pharmacother, 39, p. 1936-9

12. Gordinier ME, Dizon DS (2005) "Dyspnea during thalidomide treatment for advanced ovarian cancer." Ann Pharmacother, 39, p. 962-5

13. Horowitz SB, Stirling AL (1999) "Thalidomide-induced toxic epidermal necrolysis." Pharmacotherapy, 19, p. 1177-80

14. Bennett CL, Angelotta C, Yarnold PR, et al. (2006) "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer." JAMA, 296, p. 2558-60

15. Hamnvik OP, Larsen PR, Marqusee E (2011) "Thyroid dysfunction from antineoplastic agents." J Natl Cancer Inst, 103, p. 1572-87

16. Hanje AJ, Shamp JL, Thomas FB, Meis GM (2006) "Thalidomide-induced severe hepatotoxicity." Pharmacotherapy, 26, p. 1018-22

17. Hamadani M, Benson DM Jr, Copelan EA (2007) "Thalidomide-induced fulminant hepatic failure." Mayo Clin Proc, 82, p. 638

18. Passeron T, Lacour JP, Murr D, Ortonne JP (2001) "Thalidomide-induced amenorrhoea: two cases." Br J Dermatol, 144, p. 1292-3

19. Feaver AA, McCune DE, Mysliwiec AG, Mysliwiec V (2006) "Thalidomide-induced organizing pneumonia." South Med J, 99, p. 1292-4

Further information

Thalomid side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.